2024 Dystroglycanopathies Patient & Family Conference
Friday and Saturday, July 12 - 13, 2024
Hyatt Regency Coralville Hotel & Conference Center
Iowa MDSRC Renewal Through 2025
We are pleased to announce that the University of Iowa's Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center (MDSRC) was renewed through June 2025. Center funding comes from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health under Award Number P50NS053672.
The Iowa Wellstone MDSRC is excited to share the latest research from Dr. Kevin Campbell's laboratory: N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy, published in eLife and Identification of a short, single site matriglycan that maintains neuromuscular function in the mouse, recently published as a pre-print in bioRxiv.
Major Theme, Goals, and Objectives of the Iowa MDSRC: Therapeutic Strategies for the Treatment of Various Muscular Dystrophies
Muscular dystrophies are a diverse group of inherited disorders characterized by progressive muscle weakness and wasting. The major theme of the University of Iowa MDSRC is to translate research discoveries on the structure and function of dystroglycan into clinical applications for the diagnosis and treatment of patients with dystroglycan-related muscular dystrophy. The overall goal is to explore therapeutic strategies for the treatment of various muscular dystrophies arising from the abnormal processing of dystroglycan (dystroglycanopathies). The MDSRC works to achieve this overall goal by conducting basic and translational research in dystroglycanopathy patients and patient-derived biosamples.
The dystroglycanopathies are a phenotypically and genetically heterogeneous group of congenital/limb-girdle muscular dystrophies (CMD/LGMD) caused by hypoglycosylation of alpha-dystroglycan (α-DG). Fully glycosylated α-DG links the transmembrane b-DG protein to the extracellular matrix, a linkage critical for stability of the sarcolemma, as well as for development of the brain and eye. Currently, at least eighteen genes are known to be required for proper α-DG glycosylation. Hypoglycosylation of α-DG results in a range of clinical phenotypes, from Walker-Warburg syndrome, in which muscular dystrophy is accompanied by severe eye and brain malformations (most severe), through adult-onset LGMD (least severe); the genotype does not reliably predict phenotype.
The Iowa MDSRC is composed of two research projects and three cores. Center funding comes from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health and was renewed through June 2025 under Award Number P50NS053672. Key leadership for the Iowa MDSRC is: Kevin P. Campbell, PhD, Director of the Center and Lead Investigator for the basic and translational science Project 1; Steven A. Moore, MD, PhD, Co-Director of the Center and Lead for the national shared resource Muscle Biopsy and Cell Culture Repository; and Katherine D. Mathews, MD, Lead Investigator for the clinical research Project 2. Drs. Campbell, Mathews, and Moore share responsibility for administration and for research training and education. The Center investigators have a proven track record of excellence and collaboration in basic, translational, and clinical research on muscular dystrophy.